Nectar Lifesciences bought back shares at ₹27 per share through a tender offer that ran from 31 December 2025 to 6 January 2026 (record date 24 December 2025), with the shares listed on the BSE, NSE. Shareholders on the register on 24 December 2025, the record date, were eligible to tender. The offer covered 3,00,00,000 shares, 13.38% of the equity, about ₹81 crore.
The buyback price was 50.7 percent above the closing price of ₹17.92 on 3 December 2025, the last close before the offer; a small shareholder could tender up to 7,407 shares within the two-lakh-rupee limit. Nectar Lifesciences is a research-driven, fully integrated pharmaceutical company. Its core business revolves around the manufacturing of active pharmaceutical ingredients, mainly cephalosporin antibiotics and intermediates. It has also ventured beyond APIs into contract manufacturing of FDFs/formulations such as tablets, capsules, suspensions, granules, and injectables.
They also manufacture empty hard gelatin capsules (EHGCs) and have a presence in phytochemicals / menthol-based products. The facilities of Nectar are state-of-the-art, comprising a total of 13 facilities across Punjab and Himachal Pradesh for oral and sterile drug productions, empty capsule production, and menthol or phytochemicals. These plants meet the current global regulatory requirements for EHS/cGMP, besides approbations by the international regulatory authorities for export markets. This ensures that the quality of the product is guaranteed.
| Acceptance | Shares accepted | Profit |
|---|---|---|
| 33% | 2444 | ₹22,191 |
| 50% | 3703 | ₹33,623 |
| 75% | 5555 | ₹50,439 |
| 100% | 7407 | ₹67,255 |
Before brokerage and tax, on the maximum small-shareholder holding at the last close before the offer; the offer has since closed.
| Metric | 31-Mar-25 | 31-Mar-24 |
|---|---|---|
| Net Worth | 956.11 | 1,069.25 |
| Profit After Tax | -113.68 | 4.99 |
| Reserves & Surplus | 933.68 | 1,046.82 |
| Revenue | 1,674.97 | 1,698.66 |
| Total Borrowing | 582.02 | 635.54 |
The buyback will help the company to return surplus cash to its shareholders holding equity shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders. The buyback will help the company to optimize the capital structure;
The Buyback, which is being implemented through the Tender Offer route as prescribed under the SEBI Buyback Regulations, would involve allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved.
The company believes that the reservation for small shareholders would benefit a large number of the Company's public shareholders, who get classified as small Shareholders, as per regulations 2(i)(n) of the SEBI Buyback Regulations. The buyback may help in improving financial ratios like earnings per share, return on capital employed, and return on equity, by reduction in the equity base, thereby leading to long-term increase in shareholders' vlaue;
and The buyback gives an option to the shareholders holding Equity shares of the company, who can choose to participate and get cash in lieu of Equity shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the buyback offer, without additional investment.
In a tender offer the company fixes a price, usually above the market price, and invites every shareholder who held shares on the record date to offer some or all of them back. The entitlement ratio says how many shares you may tender for every share you hold, and because most offers are oversubscribed the acceptance ratio, the share of tendered shares the company actually buys, is known only after the offer closes.
Shares are tendered through your broker during the offer window; accepted shares are paid for at the buyback price and the rest return to your demat account within a few days of the close.
Fifteen percent of every tender offer is reserved for small shareholders, defined as those whose holding in the company was worth two lakh rupees or less at the market price on the record date. Because far fewer shares are tendered in that category, its entitlement ratio is usually much higher than the general category's, and that reservation is the reason retail investors follow buybacks at all.
The figures on this page show how many Nectar Lifesciences shares fit within the limit, what they cost at the last closing price, and what the profit would be at different acceptance ratios, before brokerage and tax.
Since October 2024 the amount a shareholder receives in a buyback is taxed as a dividend in their hands at their slab rate, and the cost of the accepted shares becomes a capital loss that can be set off against capital gains. That makes the after-tax result quite different from the headline premium, and for a shareholder in a high tax bracket a buyback with a modest premium can be worth less than selling on the exchange.
Work it through for your own bracket, or ask a tax adviser, before tendering.
₹27 per share, 50.7 percent above the closing price of ₹17.92 on 3 December 2025, the last close before the offer. The premium over the market price is what made tendering worthwhile.
24 December 2025. Shareholders had to hold the shares in their demat account on that date, which meant buying them by 23 December 2025 so that delivery settled in time.
The tender window ran from 31 December 2025 to 6 January 2026. Shares were tendered through brokers, and tender forms were accepted until 6 January 2026.
Up to 7,407 shares, which is the two-lakh-rupee small-shareholder limit divided by the buyback price of ₹27. At the closing price of ₹17.92 that holding cost about ₹1,32,733.
The offer closed on 6 January 2026. The company has not published the final acceptance ratio; the table shows what the profit would have been at 33 to 100 percent acceptance. At 33 percent the profit on a maximum small-shareholder holding would have been about ₹22,191; at 100 percent about ₹67,255, before brokerage and tax.
Accepted shares were paid for at ₹27 and unaccepted shares were returned to demat accounts by 13 January 2026.
For buybacks completed after 1 October 2024 the amount received is taxed as dividend income at your slab rate, and the cost of the accepted shares becomes a capital loss that can be set off against capital gains. Confirm the treatment for your own position with a tax adviser.